Our Buisnesses

Core One has a multi-faceted business approach and incorporates multiple and complementary lines of business and business units in establishing itself as an industry leader in the rapidly growing and emerging psychedelics market space.
Bio-Pharma Research and Development
  • Vocan Biotechnologies Inc. (“Vocan”)
  • Akome Biotech Ltd.
Advancement of Psychedelic Treatments
  • Clinics
  • Psychedelic Treatments
Delivery Systems
  • Patent-pending Transmucosal ‘Thinstrip’ Delivery Technology

Vocan Biotechnologies Inc. ("Vocan") 

Renowned Scientific Leadership Team

    • Robert E.W. Hancock, CEO (see leadership page for bio)
    • Jan Burian, Chief Scientist (see leadership page for bio)
  • Operating Under Health Canada Controlled Drugs and Substances Licensed Lab
    • Psilocybin
    • DMT
  • First-to-Market with Biosynthetic Psilocybin
    • Patent Application filed (USTPO)
    • DNA Modeling Optimizing Biosynthetic Production Process Of Psilocybin
      • retains stereochemistry of natural psilocybin molecules
      • more positive effect than chemically synthetized psilocybin
        • at scale production capabilities consistent and controllable *API composition
        • cost effective
          • Vocan’s biosynthetic psilocybin $10’s to $100’s per gram
          • Chemical synthesis, and extraction of psilocybin can range between $7000 to $10000 per gram.
  • Additional Psychedelics in Production Pipeline
    • Technology has potential gene mimicry process and simple chemical modifications of biosynthesized psilocybin, for creation of addition bioidentical compounds of known & novel analogs of psilocybin and other psychedelics.

Patent Pending Technology & Delivery Mechanism

  • Our infused thinstrips will allow for efficient bioavailability (absorption) as well as controlled dosing of active ingredients and can be used to administer multiple API’s.
  • We will control all stages of production, distribution, transportation, and delivery of Thinstrips.
  • Using our patent pending Thinstrip technology, we endeavour to advance psychedelics as alternative medicine and to deliver APIs to clients in our medical clinics, as well as license our technology to other drug providers.
Efficacy
Bioavailability
Faster onset
Precise dosing

API's include, but are not limited to

PSILOCYBIN, DMT, LSD, IBOGAINE, MESCALINE, 2C-B, 2C-I, AMT, DOM, CBD, THC

R&D – cGMP API Grade Biosynthetic Psilocybin

Revenue positive

R&D: Biosynthetic Psilocybin

Our team has designed and produced a patent pending unique optimized DNA construct and producer strain that allows for time-efficient and cost-effective production of psilocybin at scale. Combined with our patent pending Thinstrips technology, we endeavour to advance psychedelic treatments through our medical clinics, and provide product and technology for use by pharmaceutical companies, clinical researchers and licensed medical professionals.

Our biosynthetic process retains the stereochemistry of natural psilocybin found in hallucinogenic mushrooms which are known to have a more positive effect than the chemically synthesized counterparts.

We will produce cGMP API grade psilocybin for use by pharmaceutical companies, API manufacturers and organizations conducting clinical trials, providing more affordable access to organizations and the process can be scaled up while consistently producing high quality cGMP product.

R&D: Biosynthetic Advantages

Financial

  • Estimated Market price is $7,000 to $10,000 USD per gram for synthetic psilocybin used in clinical trials. By using our biosynthetic expression system, pharma-grade psilocybin can be produced cost effectively for $10s to $100s of dollars.
  • By using a biosynthetic expression system, pharma-grade psilocybin can be produced cost effectively and accurately, and purified, for a fraction of the cost of other methods.

Scientific

  • All required enzymes are produced with no inhibitory sequences (no excess).
  • Optimized, fully synthetic constructs.
  • Producer strain is optimized.

R&D Revenue Model

Contract or form a joint venture partnership with a CRO/Manufacturer to produce the API grade psilocybin. The product is sold to pharma companies, other API users, and/or other organizations.
Operate a fully owned facility to produce API grade psilocybin. The product is sold to pharma companies, other API users, and/or other organizations.
License the technology to pharma companies and/or API manufacturers.

R&D Completed Milestones

01
Exclusive right to use operational laboratory facility with Controlled Drug License issued by Health Canada for production of psilocybin (located in Victoria, BC, Canada)
02
Lab equipment for research & development has been purchased and installed
03
Proprietary DNA sequences designed and constructed
04
Optimized producer strain constructed
05
Patent submission is underway by Gowling LLP

Medical Clinics

2
Clinics, Vancouver & West Vancouver
Expansion Plan
Leveraging our existing SOPs, data driven research sets, and practitioner education modules, we will roll out clinics across Canada.
+200k
Patient Database

Clinic model = Recurring revenue

Treatment plans
  • Approval of the treatment plan
  • First dosing session
  • Exploratory Therapy
  • Dosing sessions are typically scheduled 2-3 days apart
Integration therapy
  • Psychotherapists help patients integrate the experiences using different clinical psychology techniques
  • Drive habit change and outlook/mindset improvements
Ongoing care
  • Typical treatment is 6 dosing sessions with 3 integration sessions
  • Patients have access to our digital patient portal for on-going support and education to help sustain the effects of the therapy